ConductScience.org, home

Paper40980971

Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.

Henney AE and 5 others. Liver Int, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Papers, record 40980971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40980971

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.
PubMed
Journal
Liver Int
PubMed
Year
2025
PubMed
Publication types
Journal Article, Comparative Study
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.38, provisional
iCite
Revised in PubMed
2026-09-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Henney AEAlex Ehttps://orcid.org/0000-0002-8066-9470
2Riley DRDavid R
3Anson MMatthew
4Azmi SShazli
5Alam UUazman
6Cuthbertson DJDaniel J

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
LiraglutideMajor topic
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
Hypoglycemic AgentsMajor topic
Humans
Glucagon-Like Peptides
Male
Female
Middle Aged
Tirzepatide
Aged
Dipeptidyl-Peptidase IV Inhibitors
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Incretins
Semaglutide

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134956080Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34956080PubMed
238856224Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.N Engl J Med2024https://conductscience.org/library/papers/38856224PubMed
338429161Current status and future trends of the global burden of MASLD.Trends Endocrinol Metab2024https://conductscience.org/library/papers/38429161PubMed
428950422Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.Diabetes Obes Metab2018https://conductscience.org/library/papers/28950422PubMed
533667417Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33667417PubMed
635468322
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Lancet Diabetes Endocrinol2022https://conductscience.org/library/papers/35468322PubMed
736934740Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.Lancet Gastroenterol Hepatol2023https://conductscience.org/library/papers/36934740PubMed
837193038A global federated real-world data and analytics platform for research.JAMIA Open2023https://conductscience.org/library/papers/37193038PubMed
919054785Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers.Alcohol Alcohol2009https://conductscience.org/library/papers/19054785PubMed
1031591592Avoidable flaws in observational analyses: an application to statins and cancer.Nat Med2019https://conductscience.org/library/papers/31591592PubMed
1138085855Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.Hepatology2024https://conductscience.org/library/papers/38085855PubMed
1234170647Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med2021https://conductscience.org/library/papers/34170647PubMed
1338498331Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes.Diabetes Care2024https://conductscience.org/library/papers/38498331PubMed
1438253482Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.Gut2024https://conductscience.org/library/papers/38253482PubMed
1540980971Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.Liver Int2025https://conductscience.org/library/papers/40980971PubMed
1626394161Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.J Hepatol2016https://conductscience.org/library/papers/26394161PubMed
1728035202Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.Gastroenterol Hepatol (N Y)2016https://conductscience.org/library/papers/28035202PubMed
1840015951Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.Gut2025https://conductscience.org/library/papers/40015951PubMed
1938293684Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.JHEP Rep2024https://conductscience.org/library/papers/38293684PubMed
2037717295Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.Diabetes Metab Syndr2023https://conductscience.org/library/papers/37717295PubMed

See all 33 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42689015Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies.eGastroenterology2026https://conductscience.org/library/papers/42689015PubMed
42517598Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42517598PubMed
42338974The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities.Eur Cardiol2026https://conductscience.org/library/papers/42338974PubMed
40980971Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.Liver Int2025https://conductscience.org/library/papers/40980971PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40980971

GET https://conductscience.org/api/papers/v1/40980971/references?page=2